Podcasts about Acela

CHEMAȚI SĂ BIRUIM (3) „În toate aceste lucruri noi suntem mai mult decât biruitori, prin Acela care ne-a iubit.” (Romani 8:37)

U.S. and Gulf allies present a draft United Nations Security Council resolution condemning Iran's stopping commercial shipping, especially oil tankers, in Strait of Hormuz; Federal court of appeals is reportedly skeptical of the Pentagon's military punishment of Sen. Mark Kelly (D-AZ) for his part in a video reminding servicemembers they have a duty not to follow illegal orders; World Health Organization reassures the world that the handful of hantavirus deaths on a cruise ship is not the start of a pandemic like COVID or SARS; Federal Emergency Management Agency (FEMA) Review Council issues its final report recommending changes, in many cases reductions, in how the federal government helps states respond to natural disasters. We will hear from the council co-chair and talk about it with Andrew Rumbach, Co-Lead, Climate and Communities Program with the Urban Institute (34); Republican majority in the Tennessee legislature passes and the Republican governor signs into law a new congressional district map aimed at flipping the only Democratic seat in the nine member Congressional delegation to Republican; Speaker Mike Johnson (R-LA) hosts a National Day of Prayer program in the Capitol Building; Transportation Secretary Sean Duffy takes the first ride on the "Freedom 250" Acela train to celebrate America's 250th anniversary; National Capitol Planning Commission meets to consider President Trump's proposal to paint the Eisenhower Executive Office Building's gray granite exterior bright white. Learn more about your ad choices. Visit megaphone.fm/adchoices

Deb (00:03.606)Within the next seven months, up to 1.5 million Americans could lose access to a medication that they’ve relied on for decades. Not because it’s dangerous, but because a pharmaceutical giant may have lobbied the FDA to eliminate their competition. And if you’re one of them, your doctor may already have told you about this issue and stopped prescribing it.This isn’t a conspiracy theory. This is documented in federal court filings. This is happening right now. And the company that stands to profit, well, they’re the same ones manufacturing the only product that might survive.Today on Let’s Talk Wellness Now, we’re exposing the desiccated thyroid extract crisis, the corporate manipulation behind it, and what you need to do right now to protect your health. Stay with me because I’m about to share what could save your access to the medication keeping you alive.Welcome back to Let’s Talk Wellness Now, the show where we uncover the root causes of chronic illness, expose regulatory capture in healthcare, and empower you with the tools to advocate for yourself. I’m Dr. Deb, naturopathic doctor, your medical detective, and today we’re diving into one of the most consequential and corrupt healthcare decisions affecting patients right now. If you or someone you love takes Armour thyroid, NP thyroid, or any desiccated thyroid extract,for hypothyroidism or if you’ve struggled to find a thyroid medication that actually works for your body, this episode is absolutely critical. And if you have celiac disease, gluten sensitivity or corn allergies, what I’m about to reveal will make your blood boil. Now grab your cup of coffee, don’t forget your notebook and settle in because what’s happening to this medication right now is a masterclass in how pharmaceutical companies use regular Deb (02:06.544)agencies to eliminate competition, control markets, and price gouge patients. And I have all the receipts. Deb (02:20.982)Let me start with what might surprise you. Desiccated thyroid extract, or DTE as we call it, is actually one of the most oldest thyroid medications in the world. And I mean old. From the 1890s through 1970, this was the standard treatment for hypothyroidism.Now let’s really dive into that. From the 1890s to the 1970s, this was standard hypothyroidism treatment.In 1965 alone, and this is documented in peer-reviewed literature published in the Journal of Clinical Endocrinology and Metabolism, approximately four out of every five prescriptions for thyroid hormone in the United States were of natural desiccated thyroid preparations.The Journal of Clinical Endocrinology and Metabolism is a very high-end journal. Now think about that. This wasn’t some fringe therapy. This was mainstream medicine. Armour Thyroid, the most recognizable brand name, has been manufactured since the early 1900s, well over a century ago.and this is cited again in NIH bookshelf. When the FDA was officially established in 1938, Arbor thyroid was already on the market. And this is important and I want you to understand why. Under the federal Food, Drug and Cosmetic Act, any drug that was already being marketed before 1938 was automatically grandfathered into the system. That means it didn’t have to Deb (04:08.112)go through the formal FDA approval process. And this again is cited under the Federal Food, Drug and Cosmetic Act, grandfathered drugs and exemptions. And this is crucial to understanding what happens next. By the 1970s, synthetic levothyroxine, brand name Synthroid and generics became the preferred treatment. Hmm, wonder why?It was easier to standardize, came into consistent doses, and worked well for most patients, and could be mass manufactured. By the 1980s, levothyroxine had largely replaced desiccated thyroid in clinical practice, according to the American Thyroid Association 2014 guidelines for the treatment of hypothyroidism. But here’s what matters. Some patients…a very significant minority of them, never felt right on levothyroxine alone. Despite their lab work looking normal, they still had fatigue, brain fog, weight gain, cold intolerance, and depression.These patients often found relief when they switched back to their desiccated thyroid, which contains both T4 and T3 hormones, the way human thyroid naturally produces them. And this is not anecdotal. This is documented in randomized double-blind crossover studies published in Endocrine Practice.For decades, that was fine. Their doctors prescribed it, insurance sometimes covered it, patients were getting better, and the system worked really well. Until August 6th of 2025, just a short time ago, everything changed. On that date, the FDA sent letters to manufacturers, importers, and distributors of desiccated thyroid extract products stating that these medications would need an approval. Deb (06:04.654)a biologics licensed application, a BLA, to remain legally on the market. And this is cited in the FDA’s official statement, FDA’s actions to address unapproved thyroid medications. understand it says unapproved thyroid medications. However, desiccated thyroid, specifically Armour, has been approved since 1938. And this was dated August 6th through 7th, 2025.This wasn’t a guideline. This wasn’t a suggestion. It was an endorsement of action. And the timeline they gave them? Well, just 12 months to transition patients to another medication before enforcement action could begin.This was also cited by an FDA notice to the industry, animal derived thyroid products notice to industry, August 6th, 2025. Now do the math, that means August 2026, seven months from now, 1.5 million Americans currently taking this medication. And this number comes from the FDA official statement, citing that it’s an estimation of 1.5 million patients receiving prescriptions for these medications.could potentially lose their thyroid access. Now, here’s where it gets interesting. The FDA didn’t wake up in August of 2025 and decide to regulate desiccated thyroid after a century. This decision has a much longer backstory. And understanding that backstory is critical to understanding what’s really happening in this industry.The shift started in 2022. Back in September of 2022, over three years ago, an FDA branch chief sent a letter to the National Associations of Boards of Pharmacy noting that the agency had decided to designate DTE as a biological product, which would affect its eligibility for compounding. Deb (08:13.972)This also is cited in an FDA letter to the National Association of Boards of Pharmacy September 2022.Then two months later, in November of 2022, the FDA’s Office of Compounding Quality and Compliance sent a softer letter acknowledging that many Americans take medication to treat hypothyroidism and some choose to take DTE products. The letter stated that the FDA would focus enforcement on cases that pose the greatest public health risks, such as serious adverse offense or serious product quality or adulteration.also is cited by an FDA letter from Francis G. Bromel, the director, Office of Compounding Quality and Compliance, November of 2022. Now, let me just think about this for a second. If this drug has been on the market since the 1800s, been FDA approved since 1938, would we not have seen a health crisis long before 2022?I honestly don’t know of any other drug that’s been around this long that’s used by this many people. Now granted, I haven’t done the research on it either, which I can do for you guys, but I’m just thinking if a drug is on the market today and it causes harm, it doesn’t make it three years, five years before you see lawsuits everywhere. Why are there no lawsuits on this drug? Why are there no major reactions that people are seen having?Hmm, just thought. But here’s the pattern. The FDA was already laying the groundwork back in 2022, testing the waters, signaling where this was headed. The August 2025 action. Then this came down. Deb (10:09.806)August 6, 2025, the FDA announced its position publicly and sent formal letters to all DTE manufacturers, importers, and distributors. This was cited by the FDA Enforcement Action August 6, 2025, letters to manufacturers, importers, distributions of DTE products. The agency stated several concerns. First, DTE products have experienced quality and dosing issues.The FDA cited, and I’m quoting directly from their statement, over 500 adverse events reported associated with DTE products from 1968 to 2025. From 1968 to 2025, we had 500 adverse reactions? What is that math equate to?A couple a year? Come on guys, this is insane! With a substantial increase, you, between 2019 and 2020 that the agency suggested was related to voluntary recalls of sub-potent or super-potent products.This was cited in the FDA statement, over 500 adverse events reported associated with ADT products from 1968 through 2025.Second, the agency expressed concern about batch inconsistency. According to the FDA’s official statements, tablets made from the same manufacturing batches may not always provide the same thyroid hormone levels. Okay, this was cited in the FDA statement, tablets made from the same manufacturing batches may not always provide the same thyroid hormone levels. Thirdly, and I want to actually let’s back up. I want you to remember I said that Deb (12:11.216)because further down in this podcast, we’re going to talk about this. This is an important point to remember. Thirdly, the agency raised concerns about potential impurities from animal source material, including potential for viral contamination due to the animal source and supraphysiological levels of T3.the FDA statement on impurities, viral contamination and super physiological T3 levels. Now I will tell you, I’ve been prescribing armarithograde for 20 years. I’ve rarely seen a super physiological dose given of T3 in lab results, unless the patient takes their medication like four or five hours before you do the blood test, then you’ll see a false rise because you’re actually seeing the medication. You’re not seeing people walking aroundsuperphysiological T3 levels. Nobody would like that feeling. So anyway, I digress. Now let me pause here because this is where I need to give you some context that the FDA hasn’t quite emphasized yet. Of course, we have another connection and it is the China connection.So the FDA’s concerns about contaminated drugs and quality issues don’t exist in a vacuum. In 2024, the U.S. over 828,000 metric tons of pharmaceuticals, seven times the level from 2000. And here’s the kicker. China and India supply the majority of active pharmaceutical ingredients. APIs for U.S. generics accounting for 70 to 80 % of the total genericdrug supply. According to Reuters industry report in 2024, they state that China supplies 82 % of the APIs for critical drugs. Deb (14:08.204)Got to question that, right? Why are we giving all of our drug formulas to China and allowing them to import them into our country? In fact, roughly 20 % of the critical drugs have APIs exclusively sourced from China. And China controls 80 to 90 % of the global production for antibiotics and other key compounds. This was also cited by Reuters industry data thatcontrols 80 to 90 percent of the global production for antibiotics and other key compounds. Now just think about this. They control 80 to 90 percent of our medication. They control 20 percent of our critical drugs and we just put what kind of tariff on them? Hmm.In 2025 alone, the FDA issued multiple warning letters to foreign manufacturers for contamination issues and failure to follow good manufacturing practices. This is also cited by the FDA warning letters 2024 through 2025 and multiple citations to foreign manufacturing facilities. This is a systematic problem affecting the entire US drug supply, not just desiccated thyroid.So when the FDA suddenly became concerned about DTE quality and contamination, part of that concern was legitimate. But this is crucial. The same inconsistencies and contamination issues exist across the entire generic drug supply. And the FDA has not taken the same enforcement action against them. Let that sink in.They have not taken the same enforcement action against the other drug companies. So what’s behind all of this? Where is this all coming from? Hmm. Let’s address something directly, because you deserve to know it. And I’m going to cite my sources precisely so that when the medical boards have something to say about this, and they might, I have a documentation for every single word that I am about to speak. Deb (16:24.878)According to the court documents filed in October 2025, in the case ofa urine, a urine. I’m going to say that wrong. Pharmaceuticals versus Dr. George Tidmarsh from ABBV, the multinational pharmaceutical company that manufactures armor thyroid, reportedly petitioned the FDA in 2024, asking the agency to reclassify DTE as a biologic and to prohibit other manufacturers from selling unlicensed DTE products unless they havehad an investigational new drug application, we call this an IND, and a clinical development program aimed at eventual approval. This is cited in the court filing a Urena pharmaceuticals lawsuit versus Dr. George Tidmarsh, October 2025, reported by Fierce Pharma. Now let me explain why this matters and why this is one of the most brazen examples of regulatory capture I’ve ever seen in my career.AbbeVee is one of the world’s largest pharmaceutical companies. In 2024, they reported over $54 billion in revenue. Drop the mic on that one.They have the resources, the regulatory expertise, the legal teams, and the financial capacity to navigate a biologics license application process that costs between $500 million and $1 billion. Let that sink in. Deb (18:07.882)A drug that’s been on the market since the 1800s that was grandfathered in 1938 that’s making plenty of money right now. They’re going to spend 500 million to $1 billion to get a biologics license application. Why would they do that? Well, we’re about to find out. Most otherDTE manufacturers, smaller companies like Acela Pharmaceuticals, which makes NP-thyroid, and RLC Labs, which made WP-thyroid, do not have those same resources. And this is cited in Pharma Voice in 2025. Why a treatment older than the FDA is getting new regulatory scrutiny. So when you petition the FDA to reclassify a drug in a way that requires this type of expensivetime-consuming biological approval, you’re not just asking for safety. You’re asking to eliminate your competitors from the marketplace. Now, I want to be very precise here. These allegations are documented in federal court filings, and it hasn’t been approved in court. It’s also been reported by multiple industry sources, including Fierce Pharma. But I’m telling you,what has been reported in legal proceedings, not stating it as an absolute fact because you deserve to know the difference and because I have to protect my license. Now, what do we know for certain?AbbeVee is working on a biologics license application for Armour thyroid through clinical trials called Avantia. This is cited by the AbbeVee corporate statement 2025 Avantia clinical trial for Armour thyroid. A cell of pharmaceuticals has been pursuing BLA approval for NP thyroid for seven years since 2017 and it completed its phase two trials successfully in 2025. They’re now moving Deb (20:15.448)into Phase 3 trials. This is also cited by the Acela Pharmaceuticals CEO statement 2025 seven-year pursuit for BLA approval completed Phase 2 trials moving to Phase 3.RLC Labs, which manufactured WP thyroid, has made no public announcement about pursuing BLA approval and really probably don’t have a plan to do this since they’ve been off the market for some time now. About five years, I think maybe a little longer. Here’s the market manipulation.If only ABBV is successful and obtains a BLA approval for Armour thyroid, that company would effectively have a monopoly on the DDT market. And in pharmaceutical markets, monopolies historically lead to price increases.We’ve seen this pattern over and over again when turning pharmaceuticals acquired Daraprim and raised their price from $13.50 to $750 per tablet overnight. When Myelin raised EpiPen increased prices by 400 % when insulin manufacturers colluded to raise prices in lockstep. This is the playbook.use regulatory barriers to eliminate your competition and then exploit pricing power. For a drug that’s been on the market since the 1800s, guess corporate greed is everywhere. They’re not making enough money on this product already and they’re taking advantage of the rules that they can manipulate their competition by. And here’s what really makes me furious. The American Thyroid Association, the professional organization Deb (22:06.672)representing endocrinologists sent letters to the FDA commissioner on October 8th of 2025 and September 18th of 2025.advocating for continued patient access to DTEs. This is cited in the American Thyroid Association statement and letter to the FDA commissioner dated October 8th, 2025 and September 18th, 2025. The American Association of Clinical Endocrinologists issued a statement on September 9th of 2025 supporting equitable access and personalized medicine for DTE. This was also cited in the American AssociationAssociation of Clinical Endocrinologists, AACE, statement dated September 9th, 2025. Even the medical establishment, which has historically favored levothyroxine, is saying, wait, this is going too far. Patients need access to this medication. But the FDA is moving forward anyway. Why? Well, where does it always lead us? Follow the money trail.Okay, so I need to explain what a biologics license application actually is because this is where the rubber meets the road for what’s going to happen to pricing and availability. What is a BLA?A BLA is a biologics license application. It’s a formal request submitted to the FDA to market a biologic product in the United States. A biologic is defined under the Public Health Service Act section 351 as a product derived from or made using living material, in this case, animal thyroid glands. And this is cited in the FDA definition for biologic products. So they’re putting armor thyroid right Deb (23:57.377)right up with stem cells and exosomes. Think about that. Stem cells and exosomes cost thousands of dollars per application because of how they have to be harvested, stored, freezed, all of that. But we’re talking about a thyroid gland. Good Lord, people.Unlike regular drug applications for synthetic medications which follow a simpler pathway, the BLA process is designed for complex biological products like monoclonal antibodies, vaccines, and gene therapy products. It’s a much more expensive, much more time-consuming process. The BLA processis what manufacturers have to do. And we’re going to talk about that. So according to Reprocell and Forge Biologics analysis of the FDA’s BLA process, here’s what companies need to submit. First, they need to complete a clinical trial data, phase one, two, and three trials, proving safety and efficacy for desiccated thyroid. Haven’t we done that since it’s been on the market since the 1800s? Just saying.This means they have to conduct large randomized controlled trials comparing it to levothyroxine, measuring safety outcomes, efficacy outcomes, and quality of life metrics. Second,Chemistry, Manufacturing and Controls, CMC’s data. Detailed information about how the product is manufactured, quality control measures, stability testing and specifications that must be met for every batch. Third, preclinical and animal safety data. Fourth, labeling and product information. Now, I think we have labeling and product information. Deb (25:53.717)since the 1800s? But just saying. Fifth, they need Pharma Covigilance Plan, a detailed plan for monitoring safety after the product is on the market. Haven’t they had to do that since the 1800s? And they have to have a timeline. And this is the critical part. The FDA’s standard review time for a BLA is 10 months.That’s after the application is deemed complete and accepted for filing. So this is cited by the FDA standard review timeline, BLA submission, and FDA review.Now, before you even get to filing, you need to conduct the clinical trials and compile all the data that’s typically several years of work. How are you going to prove safety and effectiveness in a large clinical trial long term? What do they consider? What do they deem long term? Three months, six months, a year, two years. These companies had 10 months.Well, maybe 12. They did it a year in advance. But unless you knew this was coming, how are you going to put together a trial, enroll the people, have all the trial components set up and ready to go in less than 12 months unless you knew it was coming beforehand? Even ifhad started all their clinical trials in 2024, completing them, compiling the data, and getting a complete application ready for submission, this would likely take you through mid-2026, then add another 10 months for FDA review. We’re looking at 2027 at the earliest for most of these companies to receive a BLA application. Deb (27:54.319)But the FDA gave the manufacturers until August of 2026. That’s approximately 19 months from when the August 2025 letters were sent. Most companies cannot reasonably complete the BLA approval in that timeframe. And when I’m talking about the 19 months, I’m talking about the information they would have had earlier. Now the cost.This gets me even more frustrated. Why are we spending this kind of money? The BLL process is extraordinarily expensive. The current FDA user fee for a BLA submission is approximately $483,560 just for the filing fee. And this is cited at the FDA user fees prescription drug user fee rates for 2025.The full cost of conducting clinical trials, CMC studies, and all the supporting documentation typically ranges from $500 million to over $1 billion, depending on the scope of the trials and the complexity. And this is cited in JAMA’s network, Open2023. A cell of pharmaceuticals has been pursuing the BLA approval since 2017. That’s eight years. And it’s just now.moving into phase three trials with a planned enrollment of approximately 300 patients. This is cited by the Acela Pharmacies CEO statement of 2025. Now that’s unusual. That’s typical for this process. This is not unusual. This is typical for this process to take seven, 10 years to get approval for this. So if Abby’s the one that requested this,Abby V. And Acela started this in 2017. Was Abby V threatened by Acela that Acela might get this approval and it would be quietly done without anybody seeing it? And maybe Abby V would be left out of the market after a century? Who knows? It’s possible. Deb (30:13.112)But for smaller manufacturers without billions in revenue, this cost is completely prohibitive. And this is why this matters. When you push an old established medication through an extraordinary, expensive approval process with a compromised timeline, one of three things happen. First, only the largest companies can afford it, creating a monopoly. And when that happens, the company that holds the only approved product can set pricing withminimal competitive pressures. Two, smaller manufacturers can’t afford it and their products disappear and the market shrinks and access decreases. Three, we see a combination of both and who pays the price? Literally, patients do. Now here’s whereThere’s something I want you to really think about because this is where the regulatory argument falls apart when you look at it carefully. The FDA’s concern about DTE is that, and I’m quoting their official statement, tablets from the same manufacturing batches may not always provide the same thyroid hormone levels. This is from their FDA statement.And that’s a legitimate quality concern, right? It is. Thyroid medications have a narrow therapeutic window like any other hormone, meaning the difference between an effective dose and the dose that causes problems can be quite small. But here’s what the FDA doesn’t emphasize. Generic drugs have the exact same dosing inconsistency issue, and it’s considered acceptable and has been since we allowed generics on the market.So how does a generic drug dose work anyway? Well, for generic drugs to be approved as bioequivalent to a brand name medication, the FDA requires that the generic drugs bioavailability fall within 80 to 125 % of the brand name product. Isn’t that a dose inconsistency? Deb (32:22.894)from the brand name medication? 800 or sorry, 80 to 125%. According to the pharmacy times analysis of the FDA’s bioequivalent standards, the 80 to 125 % bioequivalence rule means that a generic drug can have 20 to 45 % variability compared to the original brand product.Now, most generics are much closer than that. The FDA study data shows that the mean difference for an AUC value between generic and reference products is about three and a half percent in the two year post-Waxman hatch period, and 80 % of the generics fall within a five percent range. But the FDA’s regulations allow for that much higher variability. And this is cited in an FDA study data mean difference for AUC.Now, let me put this in plain language. A patient could take a generic levothyroxine tablet where one batch provides, say, 75 micrograms of an active thyroid hormone. And the next batch from a different manufacturer, a different generic manufacturer, could provide up to 93.75 micrograms, 125 % of that 75. That’s an 18 microgram difference.in the same prescribed dose. Now, this is considered acceptable and patients tolerate it and this system works.Yet the FDA’s argument against DTE is that batch-to-batch inconsistency is unacceptable and requires this expensive biologic approval? That’s a double standard. So why is batch inconsistency acceptable for generic levothyroxine, but supposedly unacceptable for desiccated thyroid? I’ll give you the regulatory answer. Deb (34:29.366)because DDT is a biological product derived from an animal tissue and the FDA considers biological products to require more rigorous control. That’s the regulatory answer, but I’ll give you the real answer.because there’s no billion dollar pharmaceutical company with a patent pending on generic levothyroxine who petitioned the FDA to regulate their competitors more strictly. The inconsistency argument is legitimate, but it’s selectively applied. And that matters when you’re trying to understand whether this is really about patient safety or whether it’s about market control.Now I want to talk about something that hasn’t gotten nearly enough attention in this discussion and it’s something that makes me absolutely furious. What is Armour Thyroid? According to the official prescribing information published by AbbeV and available through rxabbev.com and the FDA’s daily med database, Armour Thyroid contains the following inactive ingredients. Calcium steroid,dextrose derived from corn, mycocrystalline cellulose,sodium starch glycolate and a opadri white coating. Now let’s talk about dextrose. Dextrose is a sugar derived from corn and while manufacturers claim that the corn derived dextrose in armor thyroid is gluten free, here’s the problem. Cross contamination during corn processing can introduce gluten proteins especially if the corn is processed in facilities that also handle Deb (36:18.808)wheat, barley, or rye. Corn sensitivity is extremely common in patients with celiac disease and non-celiac gluten sensitivity, and studies show that up to 50 % of the celiac patients react to corn proteins due to molecular mimicry, and the corn proteins look similar enough to gluten that the immune system attacks them. And this is cited by RestartMD.com.And here’s what’s documented in peer-reviewed medical literature in a 2023 case report published in Case Reports in Endocrinology. These researchers documented five patients with gluten intolerance or celiac who were taking natural desiccated thyroid. Three of those patients also reported lactose intolerance. Now these patients had to switch from DTE to liquid levothyroxine formulations to avoid the inactiveSo here’s my question. If AbbeV becomes the only manufacturer with an approved DTE product and their formulations contain corn-derived dextrose that triggers reactions in celiac patients, what are those patients supposed to do? They can’t take armor because of the corn. They can’t take compounded DTE because the FDA is banning compounding of these biologics. They can’t take NPKsor WP thyroid because those companies may not survive the BLA process. So they’re left with a synthetic version of levothyroxine which may not work for them.Now the NP thyroid and WP thyroid difference. Now here’s what’s interesting according to drugs.com comparison of inactive ingredients and P thyroid and P thyroid has calcium steroid dextrose also derived from corn, mineral oil, multi-crystalline cellulose. Deb (38:19.31)cross carmelicin sodium and a opadri to white. So NP thyroid also has corn-derived dextrose. WP thyroid on the other hand was specifically formulated to be hypoallergenic according to ROC labs, but it’s no longer available and its ingredients were inulin from chicory root and medium chain triglycerides. No corn, no gluten, no common allergies. So todayWe do not have a glandular thyroid, a DTE, that is not potentially contaminated with gluten. Yet, patients with autoimmune thyroid disease are supposed to avoid gluten.Now, some of these people can handle a DTE and many cannot, so that argument could be a mute point. But at the end of the day, the one product that we had that was designated for patients with multiple chemical sensitivities, celiac disease and coron allergies, has been off the market for a long time already.We have a monopoly problem. So if ABBV becomes the only approved manufacturer, patients with these celiac diseases and corn allergies will either be forced to take a medicine that makes them sick and triggers their immune reaction or switch to a synthetic that doesn’t adequately treat their hypothyroidism or choose to go without treatment. This is not hypothetical. This is real patients with real medical needs who are about to lose accessto the only formulation that works for their body. And the FDA’s response is silence. Deb (40:07.69)Now I want to highlight something that hasn’t gotten nearly enough attention in this discussion. Compounding pharmacies. What is a compounding pharmacy? Compounded medications are custom made by licensed pharmacists to meet a patient’s specific needs. Maybe you need a different strength that was commercially available, but you have an allergy to a filler or a dye in the commercial product. Maybe you need a liquid formulation or instead of a tablet or you need a capsule. That’s when compoundingin. And the FDA’s, this is the FDA’s definition of compounding. And for decades, compounding pharmacies have been making desiccated thyroid extract for patients who needed customization. Some patients couldn’t take the commercial products because of the dyes and the fillers, and some needed strengths that were not available. And these compounding pharmacies filled the gap.But reclassification changes everything. When the FDA reclassified DTE as a biologic in 2022 and reinforced that decision in August of 2025, explicitly stated, and I’m quoting directly from the FDA’s official statement, these unapproved animal-derived thyroid medications are not eligible for compounding because these products are regulated as biologic products under the Public Health Service Act.How can that be? These products have been approved since 1938 and the Biologics Act didn’t go into effect or doesn’t go into effect until August of 2026.So how in 2022 were they able to say that the compounding pharmacies could not make these products? Anyway, what this means is after August 2026, compounding pharmacies will no longer be permitted to compound a desiccated thyroid extract, even for patients with specific medical needs. Now, compounding pharmacies can still compound T4 and T3 separately, synthetic versions of levothyroxine and liothyronine, according to Deb (42:12.728)healing dose compounding pharmacy. These pharmacists can create custom ratios of these two synthetic hormones to approximate what a patient was receiving from a DTE. But that’s not the same thing. Some patients respond better to the whole DTE preparation than to a compounded synthetic combination. And for patients with specific allergies to standard fillers like your celiac patients that I just talked about, losing the ability to get a compounded DTE alternative isreal hardship. This is going to be a ripple effect. For a subset of patients, maybe 5 to 10 percent of those on DTE compounding was their lifeline and it was their way to get a medication formulation that worked for their unique body. When compounding goes away, these patients lose that option as well and for some it will be a significant problem. Now let’s talk about what this likely means for your wallet.The current pricing right now, according to SingleCare and GoodRx, Armour Thyroid costs approximately $150 to $157 for a 90-day supply of 60-milligram tablets, about $1.67 per tablet. With discount cards, some patients can get it down to $101 to $152 for a 90-day supply.Generic levon thyroxine costs about $70 for a 90 day supply, less than half that price. And p-thyroid costs approximately $133 for a 90 day supply of 60 milligrams with a discount card about $83 to $101.What happens after we get BLA approval? Well, here’s the pharmaceuticals pricing model. When a company spends 500 million to $1 billion to bring a product to market, including conducting massive clinical trials, the cost tens of millions of dollars they recoup in that investment through pricing power. And this is cited in the pharmaceutical pricing models. If ABBIEV is the only company with an approved BLA of DTE, Deb (44:18.248)They have pricing power. They don’t have competitors. They can set their price, whatever they want. And historically, when drugs transition from grandfather status, which is basically unregulated to formal formally approved status, prices often increase significantly, not always, but often. And typically they have to get re-approval for insurance. SoTouring Pharmaceuticals acquired DARPM and raised the price again from $1,350 to $750 overnight, a 5,000 % increase. This is the playbook.Let’s talk about insurance coverage. This is the other consideration. Insurance companies sometimes have different coverage policies for approved versions versus unapproved drugs. And right now, many insurance plans cover armor thyroid or NP thyroid, even though they’re technically unapproved because they’ve been on the market for decades and patients are on them. Once a drug becomes formally approved, insurance companies may have new contractual relationships, prior authorization requirements, or preferred drugs.list that could affect your coverage. If 1.5 million people have to get a prior auth for their insurance to cover this new medication, this is going to drive the doctor’s offices crazy. We do not have the staff to man this. We do not have the manpower. We do not have the time. This is going to interrupt people’s ability to get their medications. This is going to create chaos within the system. And some patients might see better coverage, but manymost likely are going to see worse coverage and some might find themselves in a situation where they need to try to get the drug approved first or get an approval for something else like levothyroxine and they’re going to have to document that it didn’t work and the documentation that they had from 20 years ago is probably not going to be enough because it’s not documented anywhere. It’s lost in the system after 10 years. So for patients the practical takeaway is expect Deb (46:25.774)a price increase. I would say possible, but I don’t think that’s true. think you’re going to see a price increase if they get approved. Expect possible insurance complexities, budget accordingly, talk to your insurance company now about what your coverage is going to look like in 2027 if they even know. And if you want my honest assessment of what is likely to happen,I’ll give you a scenario, 30 % likelihood. The FDA enforces the August 26 deadline and DTE products not approved by then are pulled from the market. Patients will have 30 to 90 days to transition to other medications. Some patients suffer significant symptom relapse. Compounding for DTE becomes illegal and this disruptiveness of the system creates a real hardship. Scenario two.which is 50 % likely. This is actually what the FDA commissioner, Marty McCreary suggested on August 13th of 2025 when he posted on social media. The FDA is committed to pursuing the first ever approval of desiccated thyroid access pending results of the ongoing clinical trials. In the meantime, we’ll ensure access for all Americans. Hopefully that continues. What this likely means is the FDA uses enforcement discretion to allow continuedsales while approvals are being pursued and the deadline gets extended. Maybe patients get access for another two to three years while companies work on a BLA approval. This would be the least disruptive scenario, but it’s also legally uncertain because the enforcement letters have been formally rescinded. And scenario three, which is 20 % likelihood, one or two companies get BLA approval. Those products stay on the market at higher product prices and companies, products, other companiescompanies, products are pulled, the market shrinks, availability is limited, prices are higher, but patients can still get something. This is likely if a seller successfully completes phase three trials for NP-thyroid. And my assessment is based on the regulatory language and the enforcement letters that have not been rescinded yet, that the pattern of FDA enforcement, I believe scenario two enforcement discretion with an extended time frame is most likely what we’re going to see. Deb (48:49.488)doesn’t mean patients should sit back and do nothing. It means you should be prepared for change while advocating for access. If you want to keep Arm or Thigh Right on the market, 1.5 million people need to start talking about this publicly and flooding our Congress people, Bobby Kennedy, the FDA, with what you want to see happen. We have the ability to shape this and to change this with our voice. But if we sit back on our laurels and we do absolutelynothing. What is going to happen is what the FDA wants to have happen and ABV wants to have happen because they’re going to simply think people don’t give a shit. And if the American people are going to be lazy and not want to step forward and actually start using their voice for some good and instead of just going to social media and bitching and hoping something is going to happen, well, then we’re going to get what we deserve. But if you start taking someaction and you start advocating for the things that you want. Contacting your representatives, contacting your U.S. tell them the FDA has done this. Many of them may not know this, may not be on their radar. Tell them what you want. Start going after this. Start writing to the FDA Commissioner’s Office. They have a website. They have a Commissioner’s Office at fda.hhs.gov. Be responsible.respectful, but be firm. Explain your scenario. How long you’ve been on DTE. Why levothyroxine doesn’t work. What symptoms you experience when not adequately treated. How this decision will affect your quality of life and your pocketbook. Let’s do something proactive. So let’s consider this. Moving forward, work with your provider who understands the regulatory landscape around DTE. You can discuss the evidence for and against combination therapy.You can monitor for thyroid function with free T3 and free T4 testing, not just TSH. If you’re willing to try individualized approaches, you can do that. If you need help finding a functional medicine provider who understands this issue, come to serenityhealthcarecenter.com or explorethevanari.com. It’s a self-directed functional medicine support group. And right now what is happening is going to shape how history Deb (51:19.024)is made with not just armor thyroid, but many drugs to come. And it is important for you to take action. So I want to thank you for joining me today on Let’s Talk Wellness Now. This episode is about far more than thyroid medication. It’s about your right to personalized medical treatment. It’s about your regulatory capture and corporate influence. And it’s about what happens when billion dollar companies shape healthcare policy in ways that reduce patient choice and increase their profits.this episode resonates with you or you know somebody who’s going to be affected by desiccated thyroid, please share it. Post it on social media, send it to your doctor, email it to your representatives, tag AbbeVee, tag FDA. Make noise because the only way we stop this is if we make it too politically costly for them to continue. Your voice truly matters. Your health truly matters and you deserve access to treatments that work best for your unique body.If you’re ready to explore comprehensive personalized health care that puts you in control, visit us at SerenityHealthCareCenter.com. Learn more about functional medicine approaches to thyroid and beyond and explore my new platform, Venari.com, which is a self-directed functional medicine tool. Thank you for joining me today. Until next time, I’m Dr. Deb reminding you, your health is your responsibility, your choice, and your right. Be well, stay informed, fight back.and I’ll see you in the next episode. And if you’re looking for a full citation list of this episode, you can head over to letstalkwellnessnow.com and I will post all the citations for you so you have them in your arsenal as well. Thank you again.The post Episode 259 – The Desiccated Thyroid Crisis: FDA's Unseen Impact & Corporate Manipulation first appeared on Let's Talk Wellness Now.

Jeff Nussbaum and Dan Rothschild debate the Iran war's shaky public support, the administration's failure to make a clear case for sacrifice, and whether the mission is deterrence, regime change, or just another round of mowing the lawn. Then they turn to the Democrats who won in 2025, asking whether Abigail Spanberger, Mikie Sherrill, and Zohran Mamdani are actually governing on affordability or drifting toward the usual cultural and ideological fights. Plus, in Goat Grinders, conference badges, left-side driving in St. Lucia, and the humiliations of the new Acela. Produced by Corey Wara Video and Social Media by Geoff Craig Do you have questions or comments, or just want to say hello? Email us at ⁠⁠⁠⁠thegist@mikepesca.com For full Pesca content and updates, check out our website at https://www.mikepesca.com/⁠ For ad-free content or to become a Pesca Plus subscriber, check out ⁠⁠⁠⁠https://subscribe.mikepesca.com/ For Mike's daily takes on Substack, subscribe to The Gist List https://mikepesca.substack.com/ Follow us on Social Media:⁠⁠⁠⁠ YouTube https://www.youtube.com/channel/UC4_bh0wHgk2YfpKf4rg40_g⁠⁠⁠⁠ Instagram https://www.instagram.com/pescagist/ X https://x.com/pescami TikTok https://www.tiktok.com/@pescagist To advertise on the show, contact ⁠⁠⁠⁠ad-sales@libsyn.com⁠⁠⁠⁠ or visit ⁠⁠⁠⁠https://advertising.libsyn.com/TheGist

Războiul din Iran continuă și presa internațională își pune tot mai insistent întrebări cu privire la planurile administrației Trump. Au avut ei în vedere toate consecințele unei asemenea operațiuni? După cum comentează The Wall Street Journal, ”Donald Trump a îmbrățișat intervenționismul total. Venezuela, Iran, Cuba... După ce a petrecut ani de zile denunțând intervențiile militare americane în străinătate, ocupantul Casei Albe pare să-și fi făcut o specialitate din răsturnarea, încolțirea sau asasinarea liderilor străini”. The Atlantic atenționează că ”planul israeliano-american privind înarmarea unei insurgențe kurde în Iran riscă să dea greș. Mulți iranieni și observatori se tem că milițiile etnice ar putea avea obiective teritoriale și separatiste, ceea ce ar duce Iranul pe calea dezintegrării sau a războiului civil”. Un război civil iranian ”nu este în interesul Americii”, titrează Foreign Policy. ”Israelul ar putea saluta haosul produs de prăbușirea regimului. Statele Unite și aliații săi, nu. Citeste siAdunarea Experţilor a ales noul lider suprem al Iranului. Numele său nu a fost anunţat Președintele a lansat acest război îndemnând poporul iranian să răstoarne guvernul. Poate că a presupus că regimul se va prăbuși instantaneu. Dar când nu s-a întâmplat, într-o zi sau două, și-a schimbat discursul. A început să mediteze la relațiile cu potențialii lideri din cadrul regimului și să laude intervenția SUA în Venezuela ca model perfect de urmat”. ”Confruntată cu tendințele agresive ale lui Trump, Europa trebuie să se echipeze pentru a exercita influență asupra lumii”, scrie Le Monde:   ”Trebuie să luăm în serios ce spune Trump: este gata să facă înțelegeri cu fiecare mullah și chavist de pe planetă, cu condiția ca firmele americane să pună mâna pe bogățiile Iranului sau Venezuelei. Același lucru este valabil și pentru mineralele din Groenlanda, Ucraina sau Rusia. Afacerile sunt afaceri, iar Trump intenționează să folosească forța pentru a face afaceri profitabile oriunde se găsesc, cu mâna pe armă, la fel ca puterile coloniale europene din trecut”.   The Conversation avertizează că dacă războiul va închide Strâmtoarea Ormuz, cel mai important punct de blocare a petrolului din lume, ar putea urma un haos economic global. ”Zona este una cheie pentru petroliere și transportoare de gaze naturale lichefiate, astfel încât perturbările afectează direct aprovizionarea globală cu energie. În plus, o dependență mai puțin cunoscută este aceea că o treime din comerțul mondial cu îngrășăminte trece prin strâmtoare. Atât lanțurile de aprovizionare cu energie, cât și cele agricole au fost deja destabilizate de războiul din Ucraina. Creșteri suplimentare ale prețurilor ar putea avea consecințe de amploare”. Unde se va ajunge?- se întreabă La Stampa: ”Mulți așteaptă cu o convingere aproape mesianică marea revoltă populară iraniană care va răsturna în cele din urmă regimul după decenii de opresiune. Dar există scenariul de care este îngrijorată întreaga lume: o escaladare necontrolată care va atrage noi armate în luptă pentru a transforma un conflict regional în ceva mult mai amplu.” (Sursa: Eurotopics)

Într-un context geopolitic complicat, marcat de incertitudini – mai ales în relație cu Statele Unite ale Americii – președintele francez a lansat o reflecție la nivel european cu privire la disuasiunea nucleară. Emmanuel Macron a făcut o propunere de cooperare nucleară pentru Germania și a invitat mai multe state, inclusiv România, la discuții despre extinderea umbrelei nucleare a Franței. Cum ar funcționa, politic, și mai ales tehnic o astfel de umbrelă nucleară? L-am întrebat pe Claudiu Degeratu, expert în securitate și apărare.Claudiu Degeratu: „Se trece de la conceptul de descurajare pentru teritoriul național francez. Viziunea președintelui Franței este de a extinde ideea de descurajare spre un concept de descurajare avansată, folosind întreg spațiul euroatlantic. Pentru că noile generații de rachete hipersonice sînt mult mai performante faţă de cele de acum 30 de ani, față de rachetele sovietice dinainte de 1989, parcurg distanța mult mai rapid și dacă vizează o țintă pe teritoriul francez, atunci trebuie să fii pre-poziționat avansat în altă țară pentru a anticipa, în momentul lansării acestor rachete hipersonice. Altfel, neavînd această pre-poziționare avansată, nu poți să reacționezi la timp. Franța vrea să dezvolte o nouă tehnologie de rachete și un alt sistem de monitorizare a amenințărilor nucleare, dar în același timp are nevoie și de spațiu, geografic vorbind, să poziționeze o nouă tehnologie de capabilități nucleare împreună cu aliații în anumite zone strategice pentru a preîntîmpina. Așa cum apărarea Statelor Unite se face și prin scutul de la Deveselu, deci la mii de kilometri de teritoriul american, pentru că trebuie să acopere acest decalaj de viteză, care este mult îmbunătățit la o rachetă hipersonică. (...) Umbrela nucleară americană s-a dezvoltat de la început, din timpul Războiului Rece, împreună cu un sistem de garanții pentru țările aliate. Deci, descurajarea nucleară și descurajarea convențională NATO, împreună, erau un izvor de garanții de securitate pentru toate statele membre. Nu același lucru se are în vedere în acest moment de către Franța. Franța vrea să mărească capacitatea Franței de a descuraja Federația Rusă, ceea ce este și în avantajul nostru.” Ce ar trebui să răspundă țara noastră la invitaţia de a participa la discuţiile despre umbrela nucleară franceză?Claudiu Degeratu: „Ţara noastră va merge pe calea dialogului, în sensul în care va schimba, cu siguranță, o serie întreagă de puncte de vedere, în calitate, în special, de partener strategic al Franței. Deci, cadrul este pregătit. România nu se va opune unui dialog francez cu alți aliați. Asta este foarte clar. În același timp, România, într-adevăr, trebuie să își definească poziția ca țară aliată nenucleară. Noi, în cadrul NATO, spunem că nu producem, nu stocăm, nu vom folosi arme nucleare, dar participăm la tot procesul de planificare strategică nucleară, adică avem acces la informații și ne exprimăm poziția vis-a-vis de amenințări, de starea de securitate a alianței. Același lucru se va întîmpla și în format bilateral româno-francez. Putem să imaginăm, din acest moment, faptul că România, cu siguranță, va avea un schimb constant, și profesional și politic, în materie de stare a securității, mai ales pe flancul estic. Franța se bazează pe noi, cel puțin pentru această zonă a regiunii extinse a Mării Negre, ca să participăm la această evaluare și planificare nucleară, pentru că ea nu înseamnă că trebuie neapărat să ai arme nucleare, ci trebuie să participi la partea de evaluare, de identificare a unor posibile riscuri, de identificare a unor stări de criză și așa mai departe. Acest lucru mărește și solidaritatea noastră și, în același timp, sporește și încrederea aliaților, mai ales în relația bilaterală.”Apasă PLAY pentru a asculta interviul integral! O emisiune de Adela Greceanu și Matei Martin Un produs Radio România Cultural 

Omul care a dat Capitalei primul teatru nou construit în ultimii 80 de ani - Chris Simion – îi spune lui Mohai Morar cum poți învinge sistemul în timp ce lupți pentru viața ta!Pentru unii, Chris Simion este sinonimă cu Griviței 53. Primul teatru particular construit de la zero în Bucuresti din 1946! O realizare incredibilă, dacă ne gândim câte guverne și câți zeci de miniștri ai culturii au trecut în această perioadă fără sa aibă o realizare similară. O reușită care arată ce poate face determinarea dar și coeziunea, Griviței 53 fiind construit alături de 14.000 de bucureșteni, oameni simpli care au rezonat cu nevoile orașului lor și au donat pentru o nouă instituție de cultură.Însă în spatele acestui succes se află altul: povestea de viață a lui Chris, diagnosticată cu cancer. O boală pe care a învins-o. Iar atitudinea ei în lupta cu boala este cea mai frumoasă pildă pe care o putem urma toți, zi de zi. Pentru că povestea ei ne arată puterea pe care ne-o dau încrederea în bine, credința și dorința de a trăi!Omul care și-a vândut casa pentru a face artă fără compromis, care a ales să trăiască mai departe în timp ce lupta cu cancerul, ne propune acum un nou fel de a face cultură în România.Pe scena Fain & Simplu, Mihai Morar o prezintă pe Chris Simion în rolul propriei vieți: cum învingi cancerul în timp ce construiești un teatru, cărămidă cu cărămidă.

Același număr cu cel de cercuri ale iadului Timestamps: 0:00 Intro 8:33 Paul s-a jucat în 2025 18:20 Edgar s-a jucat în 2025 29:00 Retrospectiva 2025 în gaming 36:03 Rating predicții 2025, Predicții 2026 48:16 Știri: CEO-ul Microsoft ne roagă să nu mai facem mișto de AI; RIP Vince Zampella 53:58 Diverse scandaluri AI: Larian, Sandfall, Blue Prince; Primul studio de gaming NON WOKE YouTube: https://www.youtube.com/c/jocsivorbe1416 YouTube Stream Highlights: https://www.youtube.com/c/JocȘiVorbeBits Twitch: https://www.twitch.tv/jocsivorbe iTunes: https://podcasts.apple.com/us/podcast/all-vorbe/id1331438601 Spotify: https://open.spotify.com/show/3RFgOJDgyEnpvkUQoSh0Tc Facebook: www.facebook.com/JocSiVorbe/ Instagram: https://www.instagram.com/jocsivorbe/ Discord: https://discord.gg/m5a6DDfBFc Tip Jar: https://ko-fi.com/jocsivorbe Patreon: https://www.patreon.com/jocsivorbe RSS și linkuri de download: http://feeds.soundcloud.com/users/soundcloud:users:281506836/sounds.rss

Înțelepciunea și slava Tatălui strălucesc în maiestatea lui Hristos. El este înălțat și prețios pentru toți cei care cred. Dar gloria Lui cine o poate descrie? El vine în natura Sa divină în totalitate dezvăluită – Același care a fost disprețuit și respins de om și a stat la bara de judecată a lui Pilat ca un criminal.Citește acest devoțional și multe alte meditații biblice pe https://devotionale.ro#devotionale #devotionaleaudio

Gândurile pozitive sunt cheia către succes. Este certitudinea la care a ajuns profesorul doctor Constantin Dulcan, care îi dezvăluie lui Mihai Morar cum ne putem transforma viața.Despre efectul gândirii pozitive se vorbește de mult timp. Însă care impactul real asupa reușitelor noastre? De la efectul placebo la realizări improbabile ale oamenilor din întreaga lume, efectul palpabil al gândurilor pozitive depășește orice așteptare. Și asta pentru că nu existăm ca simpli indivizi, ci suntem parte integrantă dintr-un univers extrem de complex, inteligent, expresie a unei inteligențe superioare. Este și motivul pentru care, în premieră, la conferința Fain & Simplu ținută pe scena Casei de Cultură a Studenților din Iași, profesorul Dulcan ne împărtășește convingerea sa privind evoluția speciilor și, mai ales, a omului.Privește cu alți ochi lumea în care trăiești! Și descoperă un univers de oportunități și împliniri.Azi, la Fain & Simplu, cu Mihai Morar.

CUM SĂ SCAPI DE SINDROMUL EȘECULUI „În toate aceste lucruri noi suntem mai mult decât biruitori, prin Acela care ne-a iubit.” (Romani 8:37)

Today on The Editors, Rich, Charlie, Noah, and Phil discuss the cease-fire in Gaza, the Letitia James indictment, and much more.Editors' Picks:Rich: Haley and Kamden's piece “Virginia School Board Member Sympathized With Trans-Identifying Sex Offender Who Exposed Himself in Women's Locker Room”Charlie: Alexander William Salter's piece “JD Vance Should Take the Moon Shot”Noah: Jason Rantz's piece “The Humiliating Failure of Washington State's Plastic Bag Ban”Phil: Audrey's coverage of the Jay Jones controversyLight Items:Rich: An ode to the Acela dining carCharlie: Taylor Swift songNoah: Drop ceiling tilesPhil: Bittersweet Yankees season endingSponsors:Made InDonorsTrustThis podcast was edited and produced by Sarah Colleen Schutte. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Following a wee hiatus from host knackeredness syndrome, we're back! And we're returning to our roots by talking all about British Rail's Advanced Passenger Train, and the corporate nonsense that took APT's tilting technology via about a dozen legal entities to slap it straight into the replacement Acela fleet this year! We also answer the question: was the Pendolino just the APT sold back to us? Support #Railnatter at https://patreon.com/garethdennis. Merch at https://merch.railnatter.uk. Join in the discussion at https://discord.railnatter.uk. You can also buy my book #HowTheRailwaysWillFixTheFuture: https://bit.ly/HowTheRailways

Matei 25:14–30 (NTR) 14  Căci va fi ca atunci când un om, urmând să plece într-o călătorie, și-a chemat sclavii și le-a încredințat averile lui. 15   Unuia i-a dat cinci talanți, altuia doi, iar altuia unul, fiecăruia după puterea lui; apoi a plecat. Imediat, 16    cel ce primise cinci talanți s-a dus și a făcut negustorie cu ei și a câștigat alți cinci. 17   Tot așa, cel ce primise doi a câștigat și el alți doi. 18    Dar cel ce primise unul s-a dus, a săpat o groapă în pământ și a ascuns acolo argintul stăpânului său.19    După mult timp, stăpânul acelor sclavi a venit și a început să-și încheie socotelile cu ei. 20    Cel ce primise cinci talanți s-a apropiat și a adus încă cinci talanți, zicând: „Stăpâne, mi-ai încredințat cinci talanți. Iată, am mai câștigat încă cinci!“. 21  Stăpânul lui i-a zis: „Bine, sclav bun și credincios! Ai fost credincios peste puține lucruri, te voi pune responsabil peste multe! Intră în bucuria stăpânului tău!“.22    S-a apropiat apoi și cel ce primise doi talanți și a zis: „Stăpâne, mi-ai încredințat doi talanți. Iată, am mai câștigat doi!“. 23   Stăpânul lui i-a zis: „Bine, sclav bun și credincios! Ai fost credincios peste puține lucruri, te voi pune responsabil peste multe. Intră în bucuria stăpânului tău!“.24    S-a apropiat și cel ce primise un talant și a zis: „Stăpâne, am știut că ești un om aspru, care seceri de unde n-ai semănat și aduni de unde n-ai împrăștiat, 25    așa că mi-a fost teamă și m-am dus să-ți ascund talantul în pământ. Iată aici talantul tău!“. 26    Stăpânul lui, răspunzând, i-a zis: „Sclav rău și leneș! Ai știut că secer de unde n-am semănat și că adun de unde n-am împrăștiat? 27   Atunci trebuia ca tu să-mi fi dat arginții la bancheri, pentru ca, la întoarcere, să primesc cu dobândă ceea ce era al meu.28   Așadar, luați-i talantul și dați-i-l celui ce are zece talanți. 29   Căci celui ce are i se va da și va avea din belșug, însă de la cel ce n-are se va lua chiar și ce are. 30   Iar pe sclavul acela nefolositor, alungați-l în întunericul de afară! Acolo va fi plânsul și scrâșnirea dinților!“.  Probabil ați auzit că parabola talanților se referă la a face fapte bune sau a folosi darurile și chemările date de Dumnezeu și, ca urmare, a primi răsplată sau judecată, până chiar la punctul de a pierde mântuirea. Într-adevăr, dacă citim această pildă în mod izolat, există câteva motive evidente pentru care am putea adopta acest punct de vedere. În primul rând, cele trei persoane care au primit talanții de la stăpânul care pleca în călătorie erau toți slujitori sau robi ai acelui om, ceea ce ar putea implica faptul că erau deja în împărăție, mântuiți și născuți din nou. Aruncarea celui de-al treilea sclav în întunericul de afară din versetul 30, ca urmare a faptului că nu a folosit și nu a înmulțit ceea ce i-a dat stăpânul, poate însemna pierderea mântuirii veșnice. În al doilea rând, stăpânul i-a dat fiecărui servitor un număr diferit de talanți și se aștepta ca aceștia să-i pună la treabă, să-i administreze bine și să-i înmulțească. Acest lucru ne poate face cu ușurință să ne gândim la darurile, talentele și chemările pe care Dumnezeu le-a dat fiecărui credincios și care sunt luate înapoi dacă nu sunt folosite corespunzător. Întrebare: Este al treilea rob un credincios autentic de la început, care nu a făcut suficiente fapte bune și, prin urmare, și-a pierdut mântuirea? Să presupunem că așa stau lucrurile și să citim Romani 4:4-5:Romani 4:4-5 (NTR)4  Dar plata celui ce lucrează nu este considerată un har, ci o datorie, 5  însă celui care nu lucrează, ci se încrede în Cel Care-l îndreptățește pe cel lipsit de evlavie, credința îi este considerată dreptate. După cum puteți observa, avem o problemă dacă elevăm „pilda talanților” la rangul de „fapte” în lumina a ceea ce a învățat Pavel în aceste versete: avem o mântuire prin fapte și nu doar prin credința în jertfa lui Isus. Apoi ce să mai zicem despre ceea ce a spus Isus în Ioan 6:28-29 cu privire la lucrări sau fapte? În aceste versete, Isus a fost întrebat despre ce fel de lucrări trebuie să facem pentru a-I fi plăcuți lui Dumnezeu. Probabil observați că Isus le spune ce-I place lui Dumnezeu. Însă nu erau fapte (la plural), ci o singură lucrare, iar acea lucrare este să CREDEM:Ioan 6:28-29 (NTR)28Atunci ei L-au întrebat: ‒ Ce să facem ca să înfăptuim lucrările lui Dumnezeu?29 Isus a răspuns și le-a zis: ‒ Lucrarea lui Dumnezeu este aceasta: să credeți în Acela pe Care L-a trimis El. Chiar și Isus a refuzat să laude faptele. Da, SUNTEM creați pentru fapte bune. Asta suntem. Totuși, ideea că mântuirea noastră depinde de ele și că salvarea ar fi o răsplată nu este biblică. Acum, să presupunem că slujitorul este un credincios născut din nou care nu și-a folosit darurile așa cum ar fi trebuit și nu și-a îndeplinit chemarea dată de Dumnezeu pe acest pământ. Înseamnă asta că Dumnezeu îi va lua acele daruri sau mântuirea? Romani 11:29 ne învață că „darurile și chemarea lui Dumnezeu sunt irevocabile”. Putem concluziona că această parabolă nu vorbește nici despre daruri și chemări. Este oare posibil ca acest slujitor să fi fost cineva care nu l-a cunoscut niciodată pe stăpân? Este posibil să fi avut o asemănare de credință mântuitoare autentică, dar fără fapte corespunzătoare? Cu alte cuvinte, el avea o credință moartă, similară cu cea discutată de Iacov. Să analizăm câteva indicii din text care arată că este așa: 1.      În versetul 26, stăpânul îl numește „sclav rău și leneș”. I-a numit Isus sau Dumnezeu vreodată pe copiii Săi sclavi, răi sau leneși? Nu.2.      Acest slujitor trăiește cu frica judecății. 1 Ioan 4:18 ne spune că „dragostea desăvârșită alungă frica” și credincioșii nu ar trebui să se teamă de judecată.3.      El îl percepe greșit pe stăpân. Acest slujitor îl descrie pe stăpân ca fiind un „om aspru”, dar nu nu este prezentat așa stăpânul în parabolă. Ceilalți slujitori se bucură de bunătatea și generozitatea lui. Evident, acest al treilea rob nu-l cunoștea cu adevărat pe stăpân, similar fecioarelor nechibzuite cărora mirele le spune: „Nu v-am cunoscut niciodată”. În continuare, să analizăm contextul pildei talanților. Tema întregii discuții din Matei 24 și 25 (venirea Fiului Omului ca un hoț în noapte, urâciunea pustiirii, pilda celor zece fecioare, pilda talanților, judecata oilor și caprelor) este sfârșitul timpurilor, judecata și separarea. Care va fi exact factorul determinant sau criteriul după care vor fi separați cei drepți de cei nedrepți la sfârșitul timpurilor? Acesta va fi credința în adevărul Evangheliei, care a fost însoțită de fapte. Credința fără fapte este moartă, ceea ce înseamnă că nu a existat niciodată. Talanții dați acelor trei slujitori (în contextul celor zece fecioare) trebuie să se refere atunci la adevărul Evangheliei dat tuturor oamenilor în diferite măsuri de credință și înțelegere. Pilda talanților nu vorbește despre credincioși aruncați în iad pentru că nu fac suficiente fapte bune sau că nu umblă suficient în sfințenie. În schimb, este vorba despre cei cărora li s-a dat revelația Împărăției (referindu-se la toți oamenii sau, mai precis, la liderii evrei din vremea lui Isus) și au respins-o. Ei sunt cei care primesc judecata, nu creștin...

Monday, Apple released the new versions of all its operating systems. Have you updated yet? There was a lot of news about the new Liquid Glass look, but there are plenty of other changes. Nate and Dave have been using the betas, and we discuss the big changes to iOS and your iPhone in iOS 26. Plus we have plenty of other tech news to get caught up on after the special episode last week! Watch on YouTube! - Notnerd.com and Notpicks.com INTRO (00:00) Apple Event Followup (06:05) New Apple Charger looks pretty good The new Live Translation feature also works with AirPods Pro 2 and AirPods 4 MAIN TOPIC: Big Changes with iOS 26 (13:05) MacRumors iOS 26 Feature Roundup From Apple: New features available with iOS 26 DAVE'S PRO-TIP OF THE WEEK:  iOS tricks - avoid camera smudges and change your snooze (35:50) JUST THE HEADLINES: (43:20) Bathroom doomscrolling may increase your risk of hemorrhoids Amtrak's new 160mph Acela trains take just as long as the old ones Instagram adds iPad support, finally New nuclear rocket concept could slash Mars travel time in half E-bike injuries are a massive burden, say surgeons Japanese town proposes two-hour daily limit on smartphones Sydney radio station secretly used AI-generated host for 6 months without disclosure LISTENER MAIL: From Chelsea and Todd - Amazon ends shared Prime free shipping outside your home (44:40) TAKES: Google avoids harshest penalties in landmark search monopoly ruling (47:55) Bending Spoons buys video platform Vimeo for $1.38 Billion (48:30) Opendoor board chair Rabois says company is ‘bloated,' needs to cut 85% of workforce (51:35) Mark Zuckerberg sues Mark Zuckerberg (52:25) Microsoft Patch Tuesday, September 2025 Edition (54:20) BONUS ODD TAKE: Official Star Wars Galaxy Map (55:55) PICKS OF THE WEEK:  Dave:  Amazon Kindle Paperwhite and Kindle Colorsoft Case, Lightweight and Foldable Protective Cover - Premium Leather (58:00) Nate: EOOUT 30pcs Mesh Zipper Pouch Bags, 8 Sizes Plastic Bags, 8 Colors Waterproof Pouches with slide fastener for Organization, Multipurpose for Travel, School Supplies, Office and Home Organization (01:00:10) RAMAZON PURCHASE OF THE WEEK (01:04:35)

CNN's John King zooms in with the latest national political news.Media maven Sue O'Connell discusses the sheriffs turning their jails over to ICE for detention centers, and the $850k the state spent on outside experts for prosecuting Karen Read.Boston Globe travel writer Chris Muther zooms in from Ireland to discuss some of his recent pieces ... Amtrak's Acela upgrades and his ranking of New England rest stops.Sports authority Trenni Casey discusses the start of World Cup ticket sales, and the young Phillies fan who had his home run ball taken by an adult woman, now dubbed "Phillies Karen."

Well...Trump didn't die. But he may be actively dying. And so is America. Look no further than the flashy rollout of Amtrak's pathetic new ACELA trains. Oh yeah baby. We're talking trains. We're talking Cracker Barrel. Cultural rot. Skewed priorities. PLUS, we're covering the new meme stock that's sweeping the market. Ben's new movies and tv podcast with Dillon is OUT NOW! GO WATCH the latest episode on CAUGHT STEALING ft. AUSTIN BUTLER: https://youtu.be/n9KAwLsAaZc?si=dcwSjnjG3UtYF-Dz **CHECK OUT EMIL'S LIVESTREAMS HERE: https://www.youtube.com/emilderosa Give this video a thumbs up if you enjoyed it! And please leave us a comment! It helps us! That's Cringe of Cody Ko: https://youtu.be/dTbEk0pVh2w Our AUSTIN VIDEO IS OUT! https://youtu.be/yGSs56bFzRU Sign up to watch and support the show at https://benandemilshow.com ***LINK TO OUR DISCORD: https://discord.gg/CjujBt8g ***Subscribe to Emil's Substack: https://substack.com/@emilderosa ***Trade with Ben at https://tradertreehouse.com Our episode with *Kyla Scanlon*: https://youtu.be/cIHWkY35cuc Big Tech is out of ideas (ft. ED ZITRON): https://youtu.be/zBvVGHZBpMw Arguing with a millionaire (ft. Chris Camillo): https://youtu.be/1ZUWTkWV_MM We bought suits HERE: https://youtu.be/_cM1XqA9n2U __ ZOCDOC: Stop putting off those doctors appointments and go to https://zocdoc.com/baes to find and instantly book a top-rated doctor today! MOOMOO: Click this link https://start.moomoo.com/BAES to get up to $1,000 in free stock when you make a qualified deposit. Terms and Conditions apply. Securities are offered through Moomoo Financial Inc. (MFI), Member FINRA/SIPC. The creator is a paid influencer and is not affiliated with MFI and their experiences may not be representative of other moomoo users. Investing is risky. MUD/WTR: Start your new morning ritual & get up to 43% off your @MUDWTR with code BAES at http://mudwtr.com/baes ! #mudwtrpod GOODR: If you need a new pair of sunnies, go to https://goodr.com/baes and use code BAES for free shipping! Goodr offers a 30 day money back guarantee and 100% satisfaction. __ Follow us on instagram! @ benandemilshow @ bencahn @ emilderosa Learn more about your ad choices. Visit podcastchoices.com/adchoices

It's an all new That Real Blind Tech show as Allison, Brian, David, and Jeanine are back together to talk about little tech along with a tad of A.I. Because why wouldn't they?   We kick the show off discussing the recent story of a florida man being captured on his Ring Doorbell being attacked by a bear. Yes, a bear in freaking Florida, man.   We then get our first A.I. story of the show as Taco Bell has said No Mas to A.I. Drive Through Windows.   TSA has banned some new items from being carried on to a plane, but what is more impressive is some of the items you can take on a plane with you.   We then discuss the Ally Solos Glasses which were recently announced.   We then discuss the fascinating story about where do Waymos go when they are not driving passengers? They have to go somewhere.   Next we discuss the news about Glide not coming to Europe any time soon.   Are A.I. Agents still closer to science fiction than reality? Which leads us in to complaining about stupid articles behind the paywall and then how to get around it.   Blind people get ready to rejoice as Meta is moving ahead with Facial Recognition on their next pairs of Meta Glasses. And on a related note, Meta has released six new pairs of the Meta Oakleys, well actually only six new colors for the lenses and frames.   We then discuss the fun article How to Win friends and Influence ChatBots.   And on a terrifying note, A.I. ransomWare has arrived.   We then discuss the recent announcement between the beta partnership between Be My Eyes and Amtrak. Amtrak has also finally rolled out their new Acela trains, but don't expect them to get you to your location any faster!   Apple TV Plus has hiked its price to $13 a month. Is it time to start dialing back all those streaming services?   We then talk about the all new redesign that came to the new ESPN app, but same old same old Worldwide Leader in Inaccessibility at ESPN.   And it's more of What's Pissing Off Brian Now and Watcha Streaming, Watcha Reading.   To contact That Real Blind Tech Show, you can email us at ThatRealBlindTechShow@gmail.com, join our Facebook Group That Real Blind Tech Show, join us on the Twitter @BlindTechShow 

This week, Amtrak introduced its brand new Acela trains to the Northeast Corridor, running inaugural trips between Boston and Washington. Officials say this upgrade has been a long time coming, with new "tilt" technology to provide a smoother ride and the potential for faster trips. Amtrak senior spokesman Jason Abrams talks trains with Nichole, sharing details about the new amenities and what you can expect on your next trip.

Episode 659: Neal and Toby discuss Amtrak's new Acela that will zip up and down the Northeast corridor of the United States. Then, taking a look at the 20 years since Katrina and how the city of New Orleans recovered. The guys share their stock and dog of the week which includes the Wizard of Oz and India's tariff conundrum. Finally college football is set to kick off and the headlines you should know heading into Labor Day. LinkedIn will even give you a $100 credit on your next campaign so you can try it yourself. Check out LinkedIn.com/mbd for more. Subscribe to Morning Brew Daily for more of the news you need to start your day. Share the show with a friend, and leave us a review on your favorite podcast app. Listen to Morning Brew Daily Here:⁠ ⁠⁠https://www.swap.fm/l/mbd-note⁠⁠⁠  Watch Morning Brew Daily Here:⁠ ⁠⁠https://www.youtube.com/@MorningBrewDailyShow⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

Candlelight Vigil Held for Victims of Minneapolis Shooting; Russian Air Strike Kills 15 in Kyiv | NTD Good Morning A candlelight vigil was held in Minneapolis to honor two children killed in Wednesday's school shooting at Annunciation Catholic School. Seventeen others were wounded but are expected to recover. The FBI has identified the shooter as a 23-year-old male who identified as female. President Donald Trump has ordered flags to be flown at half-staff nationwide.Russia launched one of its largest air assaults on Kyiv in weeks early on Thursday. At least 15 people are dead with more than 40 injured. Nearly 100 buildings were damaged as rescuers continue searching for survivors. Ukraine's interior minister says children were among the casualties. Ukrainian President Volodymyr Zelenskyy condemned the attack.The Trump administration is taking over management of Washington's Union Station from Amtrak, with Transportation Secretary Sean Duffy saying his department will be investing in cleaning up the station. Duffy also took one of Amtrak's new next-generation Acela trains to New York City's Penn station to announce new measures to revamp the rail hub. New York Gov. Kathy Hochul is supporting the renovation plans, and construction is set to begin in 2027 after the design is finished.

HotelAVE has grown into a $12 billion hotel asset management firm by using data to uncover profit gaps at properties, often challenging industry norms on operations and pricing strategies. The company has also built proprietary software to integrate data from multiple management systems, streamlining analysis and decision-making. Meanwhile, the Trump administration announced a multi-billion-dollar renovation of New York's Penn Station to begin by 2027, Amtrak debuted its new high-speed Acela trains, and U.S. airlines are preparing for their busiest Labor Day weekend in 15 years, with TSA expecting to screen more than 17 million passengers. Moneyball for Hotels: How a $12 Billion Asset Management Firm Finds Value Trump Administration Plans Penn Station Overhaul in NYC, Amtrak Debuts High-Speed Acelas Labor Day to Cap Busiest Summer for U.S. Airlines in 15 Years Connect with Skift LinkedIn: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/skift/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ WhatsApp: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://whatsapp.com/channel/0029VaAL375LikgIXmNPYQ0L/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Facebook: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://facebook.com/skiftnews⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/skiftnews/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Threads: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.threads.net/@skiftnews⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Bluesky: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://bsky.app/profile/skiftnews.bsky.social⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ X: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twitter.com/skift⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Subscribe to ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@SkiftNews⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ and never miss an update from the travel industry.

The speedy Acela train makes its grand debut at South Station, Boston Mayor Michelle Wu unveils the results of city's review of school transportation system, a swarm of yellowjackets attacked students in Ashland. Stay in "The Loop" with WBZ NewsRadio.

Jared Brosnan reports.

SpaceX completes a successful test launch of the world's largest and most powerful rocket — and what it could mean for the future of space travel. Also, the latest on escalating tensions over President Trump's move to fire Federal Reserve Gov. Lisa Cook. Plus, a closer look at Taylor Swift and Travis Kelce and the engagement that broke the internet. And, Amtrak launches new Acela trains throughout the Northeast with higher speeds and more space.

Headlines: – Welcome to Mo News (02:00) – What We Know About The Shooting At CDC Headquarters In Atlanta (05:15) – Putin-Trump Summit Set For Alaska on Friday (10:30) – Will U.S. Military Be Sent To Mexico To Fight Cartels? (17:30) – 6th IRS Boss In 6 Months Loses Job (22:15) – New High-Speed Acela Trains Coming To DC-NYC-Boston Corridor (25:45) – Study: Young People Less Conscientiousness, More Anxious (29:10) – AI Is Creating Billionaires At A Rapid Rate (32:20) – On This Day In History (34:00) Thanks To Our Sponsors:  – ⁠LMNT⁠ - Free Sample Pack with any LMNT drink mix purchase –⁠ Industrious⁠ - Coworking office. 50% off day pass | Promo Code: MONEWS50 – Incogni - 60% off an annual plan| Promo Code: MONEWS – Leesa – 25% off mattress, plus extra $50 off | Promo Code: MONEWS – Shopify – $1 per-month trial | Code: monews

Hour 2 Segment 1Tony starts the second hour talking about Anita Dunn testifying that former President Joe Biden was fine. Tony also talks about Amtrak will be debuting a new high-speed Acela train after years of delay. Hour 2 Segment 2Tony answers a fan YouTube chat question over what the best chain sub restaurant is. Tony then gets into another rendition of the Friday Audio Dump featuring Alex Padilla, Vice President J.D. Vance, Mark Halperin Hour 2 Segment 3Tony talks about Adam Schiff and Letitia James getting investigated. Hour 2 Segment 4Tony wraps up the second hour of the show talking about a British guy going on a boat and shooting a gun for the first time down south in the U.S. See omnystudio.com/listener for privacy information.

Hour 1 Segment 1Tony starts the show talking about the FBI arresting Suffolk County Sheriff Steven Thompkins after being charged with extortion related to a Boston cannabis business. Tony also talks about Pam Bondi offering a $50 million bounty for the arrest of Nicolas Maduro. Hour 1 Segment 2Tony talks about Nancy Pelosi wanting to have surgeries for trans people, also hanging a trans flag outside. Hour 1 Segment 3Tony talks about Kristi Noem getting offended with her portrayal on South Park, meanwhile Vice President J.D. Vance and Charlie Kirk handled their portrayal very well. Tony later talks about Nancy Mace going off on a reporter after being fact checked. Hour 1 Segment 4Tony wraps up the first hour of the show talking about cattle prices hitting an all-time high as consumers preferring beef over other meats. Hour 2 Segment 1Tony starts the second hour talking about Anita Dunn testifying that former President Joe Biden was fine. Tony also talks about Amtrak will be debuting a new high-speed Acela train after years of delay. Hour 2 Segment 2Tony answers a fan YouTube chat question over what the best chain sub restaurant is. Tony then gets into another rendition of the Friday Audio Dump featuring Alex Padilla, Vice President J.D. Vance, Mark Halperin Hour 2 Segment 3Tony talks about Adam Schiff and Letitia James getting investigated. Hour 2 Segment 4Tony wraps up the second hour of the show talking about a British guy going on a boat and shooting a gun for the first time down south in the U.S. Hour 3 Segment 1Tony starts the final hour of the show talking more about the racial fight in Cincinnati and how the woman wants the onlookers who didn’t help to be prosecuted. Hour 3 Segment 2Tony is joined with E.J. Antoni, economist from the Heritage Foundation, to talk about the GDP and the economy with the divide between Wall Street and Main Street. Hour 3 Segment 3Tony continues his conversation with E.J. Antoni, economist from the Heritage Foundation, talking about tariffs influencing Toyota. Hour 3 Segment 4Tony wraps up another edition of the show talking about a pro-Palestine woman wanting to burn down every American government form. See omnystudio.com/listener for privacy information.

The long-awaited rollout of Amtrak's new Acela Express trains, highlighting their innovative features and the challenges faced during development. The conversation then shifts to the importance of public art in urban spaces, exploring the impact of NIMBYism on art installations and the necessity of integrating art into city planning for community engagement and identity. In this engaging conversation, the hosts explore various urban planning topics, including the humorous saga of a splash pad in Santa Barbara, the challenges of San Francisco's Vision Zero initiative aimed at reducing traffic fatalities, and insights into bicycle infrastructure and innovative urban planning examples. The discussion highlights the complexities and absurdities of city planning, community engagement, and the importance of effective infrastructure for public safety and accessibility.Send us a question: radiofreeurbanism@gmail.comPatreon: patreon.com/RadioFreeUrbanismSully: https://www.youtube.com/@SullyvilleEthan: https://www.youtube.com/@climateandtransitNic: https://www.youtube.com/@nicthedoor

Presa europeană salută, în general, decizia președintelui american Donald Trump de a sprijini Ucraina, inclusiv cu rachete Patriot. Este analizat și ultimatumul de 50 de zile până la un armistițiu, adresat Rusiei. Însă nu toți comentatorii sunt optimiști. ”Donald Trump ia act de propriul eșec în războiul din Ucraina. El promite arme pentru Kiev și sancțiuni pentru Moscova”, titrează Le Monde. ”O parte din anturajul său prezent luni în Biroul Oval fusese martoră, sau chiar participase, în cazul vicepreședintelui său, la mustrările severe adresate președintelui ucrainean. Autoproclamat adversar al asistenței militare americane către Kiev, J.D. Vance a păstrat tăcerea de data aceasta”. The Irish Times notează că „insistența lui Trump că SUA nu vor plăti pentru arme va contribui mult la liniștea opoziției vocale din cadrul mișcării sale MAGA față de orice implicare directă a SUA în război.” (Sursa: Eurotopics) „Este dificil de știut cu precizie cât de mari ar trebui să fie cheltuielile militare pentru a face diferența și a-l obliga pe Vladimir Putin să ia în considerare un armistițiu”, analizează cotidianul britanic The Guardian, adăugând că, totuși, „orice sumă de peste 10 miliarde de dolari ar trimite un semnal puternic Moscovei, având în vedere cele 67 de miliarde de dolari deja plătite Ucrainei de Joe Biden în aproape trei ani”. Același ziar constată că ”încercările lui Putin de șantaj nuclear, care l-au tulburat atât de tare pe Joe Biden, sunt demne de dispreț. Dacă ar avea curajul, NATO l-ar putea băga înapoi pe Putin în cutia lui În schimb, ”o înfrângere pentru Ucraina și o înțelegere în termenii hegemonici ai lui Putin ar fi o înfrângere pentru Occident în ansamblu - un eșec strategic care ar prevesti o eră de conflict permanent și tot mai extins în întreaga Europă.” Ziarul belgian Le Soir constată că ucrainenii au învățat să trăiască cu „valurile de atacuri cu drone rusești, iar pe de altă parte, cu salvele mediatice ale lui Donald Trump care rezonează în mass-media globală ca un foc de tun”. Cât despre Zelenski, ziarul belgian observă că ”după ce a demonstrat, în Biroul Oval, în timpul altercației din 28 februarie, că nu este pregătit să îngenuncheze în fața nimănui”, acesta a ales cartea ”concilierii și a dialogului cu omologul său american”. (Sursa. Courrier International). Ceva mai sceptic, Frankfurter Allgemeine Zeitung nu vede nicio schimbare majoră în gândirea lui Trump: Trump ”dorește să transfere costul armelor către europeni. Ceea ce înseamnă că Europa va trebui probabil să plătească și mai mult pentru Kiev decât a făcut-o până acum. Nu toți miniștrii de finanțe ai continentului și-au dat seama încă de acest lucru. Și Trump nu este interesat ca Ucraina să câștige, așa cum a cerut Biden. Ceea ce își dorește este un acord de pace și un Premiu Nobel. Dar fără concesii semnificative din partea Kievului, este greu de imaginat că va obține ceva din toate acestea.” (Sursa: Eurotopics) Ziarul italian La Stampa vede o problemă în termenul limită de 50 de zile stabilit de Trump: ”Cu alte cuvinte, America va permite armatei ruse să profite din plin de vară pentru a-și continua ofensiva  în care Kremlinul își investește toate resursele”.

Markus Moore, Director of Transportation for the City of Annapolis, joins Paul Comfort from the rooftop of the Hillman Garage during Naval Academy Commissioning Week for a wide-ranging conversation about his remarkable journey through transit. From helping launch high-speed rail in North America as part of the Acela project at Amtrak, to managing local bus and on-demand service in Maryland's historic capital city, Markus brings decades of cross-modal experience and leadership to the mic.This interview is a companion episode to an upcoming Transit Unplugged TV episode focused on Maryland's transit ecosystem, featuring Annapolis, Howard County, and MTA. In This Episode:What it means to run transit in a state capital with high seasonal and political visibilityThe evolution of Annapolis's fixed-route, paratransit, and on-demand servicesReflections on the launch of high-speed rail in the U.S. via the Acela projectHow Commissioning Week and tourism reshape service in a city like AnnapolisThe rollout of electric buses and steps toward a greener fleetCollaboration with MTA, RTA, and other regional transit partnersCareer lessons from rail, freight, and bus systems across the U.S. Podcast Credits:Transit Unplugged is brought to you by ModaxoCreator, Host, + Producer: Paul ComfortExecutive Producer: Julie GatesProducer + Newsletter Editor: Chris O'KeeffeAssociate Producer: Cyndi RaskinSpecial thanks to: Brand Design: Tina Olagundoye Social Media: Tatyana MechkarovaGot a question or comment? Email us at: info@transitunplugged.com Subscribe to the Transit Unplugged Newsletter:transitunplugged.com/subscribe-to-the-transit-unplugged-newsletterFollow us on social media:YouTube: @transit-unpluggedX (Twitter): @TransitUnplugInstagram: @transitunpluggedThreads: @transitunplugged Disclaimer:The views and opinions expressed in this program are those of the guests, and do not necessarily reflect the views or positions of Modaxo Inc., its affiliates or subsidiaries, or any entities they represent (“Modaxo”). This production belongs to Modaxo and may contain information that may be subject to trademark, copyright, or other intellectual property rights and restrictions. This production provides general information, and should not be relied on as legal advice or opinion. Modaxo specifically disclaims all warranties, express or implied, and will not be liable for any losses, claims, or damages arising from the use of this presentation, from any material contained in it, or from any action or decision taken in response to it.

Katulad ng iba, may tinatagong pagtingin si Acela sa kanyang kababata kaso kapatid lang talaga ang turing sa kanya ni Greg. Ayos lang kay Acela iyon, tinutulungan niya pa nga si Greg sa tuwing kailangan nitong i-surprise ang girlfriend niya. Hanggang sa nagkaroon ng pandemic, napadalas ang pag-aaway ni Greg at ng kanyang gf. Bilang kapitbahay ni Acela si Greg, madalas itong nasa bahay nila. At nang magkainuman sila, hinayaan ni Acela na may mangyari sa kanilang dalawa. Nabuntis si Acela pero ayaw iyon panagutan ni Greg. At kahit alam niyang magagalit si Greg, pumayag si Acela na maikasal silang dalawa. Pakinggan ang kwento ni Acela sa Barangay Love Stories.

Julius Nyanda is the Founder and CEO of HouseKeys, unlocking housing opportunity for cities, developers, homeowners, and renters. HouseKeys is a civic tech platform that helps local governments manage affordable and mixed-income housing programs across ownership, rental, and finance. Through its Program Marketplace, Julius and his team streamline administration and expand access to community-driven housing solutions, supporting cities like Beverly Hills, Morgan Hill, and San Francisco in delivering scalable, equitable outcomes.(03:22) - Challenges in Affordable Housing Development(06:10) - Housing policy incentives for Investors(10:46) - HouseKeys Marketplace approach(13:04) - The Economics of Affordable Housing(14:10) - GovTech & VC Opportunities & Challenges(22:37) - Feature: Blueprint 2025: The Future of Real Estate - Register now (23:23) - California's New YIMBY Bills(26:29) - AI & the Future of Housing Solutions(37:07) - Collaboration Superpower: Robert F. Smith (CEO at Vista Equity Partners) & Jack Ma (Founder of Alibaba)

Vicepreședinte român al Parlamentului European: „Dacă România nu se schimbă, la putere va veni „tatăl” lui Georgescu” (Adevărul) - Un important sociolog oferă o explicație pentru apariția „poporului lui Georgescu” (HotNews) - România online | Ce se ascunde în spatele războiului pentru atenție de pe rețelele de socializare (Europa Liberă) - Joaca de-a naziștii în România. Amenințări cu pistolul la tâmplă sau cu decapitarea, ignorate de autorități pe motiv că anchetele costă prea mult (Libertatea) „Coliva" lui Georgescu și bătălia lui Simion (SpotMedia)Odată cu validarea de către CCR a candidaturii lui George Simion se schimbă paradigma electorală.O certitudine este că marea majoritate a voturilor lui Călin Georgescu se vor diviza între George Simion și Victor Ponta, care este de așteptat să preia masiv din pesediștii captați de Georgescu și care nu au niciun interes pentru Crin Antonescu.Cine cât va lua depinde în linii mari de două întrebări-cheie ale zilelor viitoare1.Ce va face Călin Georgescu? Singurul mesaj pe care aceasta l-a transmis după invalidarea de către CCR este că și-a încheiat misiunea și fiecare să facă ce și cum îl duce capul la alegerile din mai...Lipsa susținerii ar putea să-l coste pe Simion câteva procente decisive pentru intrarea în turul al doilea. Este probabil ceea ce vrea și Calin Georgescu, pentru că odată intrat Simion în finală, Georgescu va dispărea cu totul.2.Ce va face Anamaria Gavrilă?Înțelegerea era că se vor înscrie și Simion și Gavrilă, ca plasă de siguranță, însă dacă vor fi validați se va retrage cel mai post clasat. Dacă dna Gavrilă nu se retrage sau nu o face înainte de fi tipărite buletinele de vot, va ciupi câteva mii de voturi de la Simion. Și cum lupta pentru turul al doilea se anunță teribilă, fiecare vot contează.Nu aș exclude, scrie jurnalista Ioana Ene Dogioiu pe pagina SpotMedia, ca însuși Călin Georgescu să o țină acolo tocmai pentru ca Simion să rateze turul al doilea și el să poată redeveni liderul izolaționiștilor.Vicepreședinte român al Parlamentului European: „Dacă România nu se schimbă, la putere va veni „tatăl” lui Georgescu” (Adevărul)Nicu Ștefănuță, vicepreședinte român al Parlamentului European, susține că România nu are o infrastructură industrială care să-i permită obținerea de fonduri europene masive pentru producția de armament, dar poate să se pregătească pentru război construindu-și o „infrastructură beton”.Independentul Nicu Ștefănuță, al doilea vicepreședinte român al Parlamentului European, a explicat pentru „Adevărul” că în situațiile de criză, cum a fost pandemia și cum este acum războiul din Ucraina, banii necesari pentru gestionarea problemelor sunt luați de la țările care nu au reușit să acceseze fondurile.În acest context, România stă foarte prost, în condițiile în care timp de un an și jumătate politicienii s-au concentrat doar pe alegeri și nu pe atragerea și ducerea la finalizare a proiectelor finanțate din fonduri europene.Ștefănuță avertizează că „dacă România nu se schimbă și mergem la fel ca până acum, peste patru ani nu va veni un Georgescu, ci va veni „tatăl” lui Georgescu”.INTERVIU. Teoria restanțelor la plata facturilor. Un important sociolog oferă o explicație pentru apariția „poporului lui Georgescu” (HotNews)“Poporul român” a renăscut în noiembrie 2024 pentru că un anume Călin Georgescu l-a făcut vizibil. Același “popor român” este dorit la vot, în mai 2025, pentru a alege, printre alții, pe succesorii lui Georgescu: George Simion sau Ana Maria Gavrilă.. Cine este acest “popor român”? L-am întrebat pe sociologul Dumitru Sandu, unul dintre cei mai respectați sociologi români.În interviul pentru Hotnews, Dumitru Sandu analizează ultimul sondaj Europol care relevă două tendințe clare:“Miscările sociale de protest și nemulțumire din România par să fi fost stimulate, în principal, de proasta funcțonare a instituțiilor, de corupția instituțională care a dus la această situație.” Sănătatea este, din acest punct de vedere, pe primul loc.Preocuparea privind Sănătatea este cea a bărbaților care nu mai sunt așa tineri și au dificultăți în plata facturilor lunare. Ei se întreabă: în situația dată de vârsta mea, de perpetuarea datoriilor mele, mă pot baza pe Spital, doctori? Răspunsul este Nu!”România online | Ce se ascunde în spatele războiului pentru atenție de pe rețelele de socializare (Europa Liberă)În România, 13 milioane de oameni folosesc rețele sociale la nivelul anului 2025, arată ultimele date de la DataReportal. Asta înseamnă că 68,6% din populația totală a României e conectată la social media.Cât de mult influențează informația primită de algoritmii social media deciziile din viața reală? Cum arată România online? Cum poate fi depistat un fake news?Europa Liberă a stat de vorbă cu oameni obișnuiți - utilizatori de social media, experți media, profesori care se ocupă de combaterea dezinformării și psihologi. Încercăm să explicăm mecanismele prin care suntem sau devenim victime ale manipulării pe internet.România preia în 2025 măsuri dure de protecție adoptate de Uniunea Europeană încă din 2022În pragul alegerilor prezidențiale programate pe 4 mai, Guvernul și Autoritatea Naţională pentru Administrare şi Reglementare în Comunicaţii (ANCOM) pregătesc o ordonanță de urgență împotriva campaniilor de fake-news din online.Măsurile ar trebui să intre în vigoare înainte de începerea campaniei electorale, adică înainte de 4 aprilie.Joaca de-a naziștii în România. Amenințări cu pistolul la tâmplă sau cu decapitarea, ignorate de autorități pe motiv că anchetele costă prea mult (Libertatea)Valul de neonazism promovat intens în ultimele luni de mișcările de extremă dreaptă se manifesta violent în România de cel puțin doi ani. Derapajele adepților acestui curent, care a ajuns să pună în pericol securitatea națională, au fost tratate însă cu indulgență de autorități. Adepții care au amenințat oameni nevinovați cu pistolul la tâmplă, cu moartea prin decapitare sau aruncatul cadavrelor în gropi comune au primit pedepse cu suspendare sau amânare.  Au fost inclusiv cazuri când procurorii au renunțat la anchetă, invocând un efort financiar și uman mult prea mare în raport cu gravitatea faptelor, iar infractorii au rămas neidentificați.Exemple concrete în ziarul Libertatea.

El va face ca lumina Sa să pătrundă în încăperile minții și în templul sufletului, dacă oamenii, când le lipsește înțelepciunea, vor merge în cămăruța lor de rugăciune și vor cere înțelepciune de la Acela care oferă tuturor fără plată și fără ceartă.Citește acest devoțional și multe alte meditații biblice pe https://devotionale.ro#devotionale #devotionaleaudio

In this episode of Transit Unplugged, host Paul Comfort interviews Stephen Gardner, CEO of Amtrak, at their Washington, DC headquarters. They discuss Amtrak's record ridership of 32.8 million passengers in the past year, recent capital investments totaling $4.5 billion, and the introduction of new Acela trains. Gardner shares insights into Amtrak's strategy to double ridership by 2040, high-speed rail initiatives, and the unique structure of Amtrak as a federally-owned yet commercially-operated entity. Key projects such as the Frederick Douglass Tunnel in Baltimore and the upcoming Gulf Coast service are also highlighted, along with Amtrak's approach to modernizing and expanding its network. The episode concludes with a look into the future of rail travel and the importance of strategic partnerships. 00:00 Welcome to Transit Unplugged 00:05 Introduction to today's episode from host Paul Comfort 01:24 Interview with Stephen Gardner 01:34 Stephen Gardner's Background and Role at Amtrak 03:03 Understanding Amtrak's Unique Structure 07:42 Amtrak's Business Model and Operations 13:23 Challenges and Opportunities in Rail Expansion 23:02 High-Speed Rail and Future Projects 27:18 Conclusion and Final ThoughtsNext week on Transit Unplugged, Paul chats with Mikel Oglesby, General Manager of SunTran, SunRail, and SunLink, in Tucson, AZ. Transit Unplugged is brought to you by Modaxo https://www.modaxo.com Host: Paul Comfort Producer: Paul Comfort Writer: Cyndi RaskinExecutive Producer: Julie Gates Special thanks to: Brand design: Tina Olagundoye Social Media: Tatyana Mechkarova Transit Unplugged Newsletter & Media Support: Cyndi Raskin Disclaimer: The views and opinions expressed in this program are those of the guests, and do not necessarily reflect the views or positions of Modaxo Inc., its affiliates or subsidiaries, or any entities they represent (“Modaxo”). This production belongs to Modaxo, and may contain information that may be subject to trademark, copyright, or other intellectual property rights and restrictions. This production provides general information, and should not be relied on as legal advice or opinion. Modaxo specifically disclaims all warranties, express or implied, and will not be liable for any losses, claims, or damages arising from the use of this presentation, from any material contained in it, or from any action or decision taken in response to it.

CINE FACE PARTE DIN VIAȚA TA! „Acela despre care îţi voi spune: ‘Acesta să meargă cu tine' va merge cu tine, şi acela despre care îţi voi spune: ‘Acesta să nu meargă cu tine' nu va merge cu tine”. (Judecători 7:4)

Poporul lui Dumnezeu trebuie să se umple de bucurie sfântă, astfel ca razele care pornesc de la el să strălucească și să lumineze calea altora. Ce putere, ce pace, ce bucurie poate avea sufletul care este unit cu Hristos! Splendoarea divină li se descoperă tuturor celor care relaționează strâns cu Acela care este sursa puterii. Citește acest devoțional și multe alte meditații biblice pe https://devotionale.ro #devotionale #devotionaleaudio

Urmașii lui Hristos sunt trimiși în lume cu un mesaj de pace. Acela care, prin influența tăcută și neconștientizată a vieții lui sfinte, va manifesta iubirea lui Hristos; acela care, prin cuvinte și fapte, îi va determina pe alții să renunțe la păcat și să-și predea inima lui Dumnezeu este un aducător de pace. Citește acest devoțional și multe alte meditații biblice pe https://devotionale.ro #devotionale #devotionaleaudio

Singura cale de a avea parte de pace și de bucurie este să avem o legătură vie cu Acela care Și-a dat viața pentru noi, care a murit ca noi să putem trăi și care trăiește ca să-Și unească puterea cu eforturile celor care se luptă să câștige. Citește acest devoțional și multe alte meditații biblice pe https://devotionale.ro #devotionale #devotionaleaudio

CREDE CĂ DUMNEZEU VA FACE LUCRURI MAI MARI! „Acela care a început în voi această bună lucrare o va isprăvi…” (Filipeni 1:6)

Nimeni nu trebuie să piardă viața veșnică. Oricine alege zilnic să învețe de la Învățătorul ceresc își va face sigură chemarea și alegerea. Să ne umilim inima înaintea lui Dumnezeu și să continuăm să-L cunoaștem bine pe Acela a cărui cunoaștere înseamnă viața veșnică. Citește acest devoțional și multe alte meditații biblice pe https://devotionale.ro #devotionale #devotionaleaudio

Speaking with Randell Moody of the American Dream podcast in CT, his business and entrepreneurial spirit with Lifewave, and his excellent hip hop music as artist Pryme Minister. We talked about my experiment to try to Waze my Amtrak ride home on Acela's high speed locomotive and how Waze had a hard time keeping up with the high speed from the Amtrak train. I asked Randell about his most positive podcast guest, Panama Jill and how she prevailed after losing an eye, and how she kept going. Randell also discussed her free painting. Other subjects discussed, my friend Rich A from NJ and his amazing entrepreneurial spirit in his dumpster recycling business. We also play some music including Pryme Minister Do The Billy (hip hop) and Bruce Chamoff Peppermint (pop). We talk about Randell's business Lifewave and how he achieved over 900 sales in his first year and about his involvement in the company. About Lifewave LifeWave is a wellness company founded in 2004 that offers a range of health products, primarily focusing on wearable patch technology. Their signature products are adhesive patches designed to stimulate acupuncture points on the body to improve health and wellness. The company claims that these patches, which do not deliver substances into the body, instead use phototherapy to enhance energy, reduce pain, improve sleep, and promote overall health. The most popular LifeWave product is the X39 patch, which is said to activate stem cells to support healing and anti-aging. LifeWave promotes its products as a natural, non-invasive way to improve various aspects of health without the need for drugs or supplements. LifeWave operates under a multi-level marketing (MLM) model, meaning its products are sold through independent distributors who can also recruit others into the business. This business model has garnered both supporters who praise the product benefits and critics who raise concerns about the MLM structure. The company has expanded its reach globally and continues to attract users interested in alternative health solutions. However, the claims made by LifeWave have faced scrutiny, and potential users are encouraged to research and consult healthcare professionals before use. LifeWave's rapid growth can be attributed to a combination of innovative products, strategic marketing, and a robust business model. Here are a few key factors: Randell explains why Lifewave is the fastest growing company in the world… 1. **Unique Product Offering**: LifeWave specializes in wearable patches that utilize phototherapy. The flagship X39 patch claims to activate stem cells and promote various health benefits without drugs or chemicals, appealing to those seeking alternative health solutions. 2. **Global Appeal**: LifeWave has successfully expanded into international markets, tapping into the growing interest in wellness and biohacking worldwide. Its products resonate across cultures and age groups, driving global sales. 3. **Multi-Level Marketing (MLM) Model**: The MLM structure allows LifeWave to rapidly scale by empowering individual distributors to market the products and recruit others. This network effect leads to exponential growth as more people join as sellers and consumers. 4. **Health and Wellness Trend**: LifeWave is aligned with the booming health and wellness industry, which is projected to continue growing. The pandemic also heightened interest in immune health, anti-aging, and non-invasive treatments, all of which LifeWave products claim to address. 5. **Customer Testimonials and Word-of-Mouth**: LifeWave's success is bolstered by glowing testimonials and strong community engagement. Positive word-of-mouth and success stories are highly effective in an industry built on trust and personal experience. The Lifewave podcast monetization opportunity Lifewave is alive and well on the World Podcast Network starting with Fierce Manson of the Fierce Female Network and now Randell. We play Peppermint from Bruce Chamoff featuring  --- Support this podcast: https://podcasters.spotify.com/pod/show/successful-podcaster/support

INCOMING! Something different on the pod this week? Jake & Trey wake up to find they have a WIN to celebrate and deconstruct, and some actual NYCFC momentum to analyze and ballyhoo. Your boys in blue talk Agustin Ojeda's nasty little account opener, a deepening defensive fight, Big Bird's bedrock balls, and much more. Plus: Open Cup prognostications, Concacaf Champions conversations, and stadium vote machinations. Then: a dirty discussion of the District before this weekend's Acela matchup against DC United. Time at last to put away those winter digs; you've got Blue Balls.

Today's Post - https://bahnsen.co/49VU9Du It's been a weird week to pick a topic for the Dividend Cafe.  I have about six topics mapped out for future Dividend Cafes, yet none of them grabbed me to do this week.  I took an Acela to DC from New York on Wednesday late afternoon and felt pretty inspired about one topic, and then felt inspired about another as I took the train back to NYC 24 hours later.  I did a panel with David Malpass, recent president of the World Bank and Treasury Department Deputy Secretary for three Presidents, at the Library of Congress yesterday, and when I came off that stage, I had a whole new inspiration for today's Dividend Cafe.  I did a podcast with John Mauldin earlier in the week that put many ideas on the table (as all my talks with John always do).  We had a State of the Union address last night and experienced "Super Tuesday" just a few days ago.  The White House announced plans for credit card fee restrictions this week.  And the Fed announced a reversal of plans for onerous new "Basel 3" capital requirements on banks. Do you see what I am saying?  I have had one idea, inspiration, or fodder after another for this Dividend Cafe all week, and when it comes time to put pen to paper, the only choice I have is to do …. All of the Above! Jump on into the Dividend Cafe.  We have a lot to talk about! Links mentioned in this episode: TheDCToday.com DividendCafe.com TheBahnsenGroup.com

Unfortunately Boomer did not run into Taylor Swift in Baltimore. Boomer did run into Jim Harbaugh and told Boomer he hears his sports minutes sometimes. Boomer said there was a tense moment at the train station last night leaving Baltimore on the Amtrak Acela. There was one ‘asswipe douchebag' who approached Boomer, Nate and Cowher. He was telling them the NFL is rigged. Coach Cowher was getting into it with the guy. Then Nate started getting into it with the guy as well. And then Amtrak ran out of alcohol. Jerry returns for an update and starts with the sounds from the Lions/Niners game. Kyle Shanahan talked about the difference between the first and second half. Dan Campbell talked about going for it instead of kicking field goals, and failing. Ian Eagle had the call of the Lamar Jackson interception in the endzone. Andy Reid talked about the Chiefs defense being outstanding. In the final segment of the hour, Kadarius Toney took to social media to say he was not injured, despite what the Chiefs said. He went on Instagram live to say these things. And he cursed a lot. Boomer wonders why Gio is fascinated with Kadarius.

In this conversation, Doug Bainton, a citywide interagency coordinator in New York City, discusses the importance of interagency coordination in emergency management. He highlights the value of field experience and understanding the tactical mindset in emergency response. Doug emphasizes the need for building relationships and communication among different agencies and the benefits of working together in incident response. He also encourages emergency managers to connect with other agencies and understand their needs and capabilities. Doug shares insights on how the interagency model can be applied in other communities and the importance of leading with empathy and offering help.Connect with Doug: https://www.linkedin.com/in/dougbainton/ Support our podcast! Everything EM Weekly: www.thereadinesslab.com/em-weekly-linksThe Readiness Lab: https://www.thereadinesslab.com/Connect with me! https://www.linkedin.com/in/zborst/Leading During Crisis is a Masterclass taught by Pete Gaynor, who held one of the highest offices in the federal government while leading the nation through numerous disasters: https://courses.femapete.com/a/2147740050/5SZFSgu7Major Endorsements:L3Harris Technologies' BeOn PPT App. Learn more about this amazing product here: www.l3harris.comPropper International: From the outdoors to the EOC, wear Propper. www.propper.comPaladin by Acela, Inc.: Riding to the final destination with the Cube, a mobile MCI refrigerated morgue: www.paladinprepare.comImpulse: Bleeding Control Kits by professionals for professionals: https://lnkd.in/dWWBYJAaDoberman Emergency Management Group provides subject matter experts in planning and training: www.dobermanemg.com

Listen, Watch, & Support DTP: www.thereadinesslab.com/dtp-linksBoost the Signal with a $5 monthly donation!Become a TRL Insider Member with a ton of extra content!#emergencymanagement #disastertough #leadership #emergencyservices ---“Pivoting is not the end of the disruption process, but the next leg of your journey”.David Ronsen of Acela, Inc. knows this concept all too well as he continues to innovate in the world of emergency response. David has worked in or adjacent to emergency response for three decades. As such, he has pivoted specialties many times. From working as a firefighter to designing and constructing vehicles for firefighting, mining, oil, and gas, and later working with the VA during the COVID-19 Pandemic to construct and distribute morgue trailers, David says the importance of pivoting and reinventing yourself is key to continued success in any field, let alone Emergency Management and response.In this episode, David talks about how he developed, constructed, and distributed nearly 50 morgue trailers in just over a month during the pandemic. He also relates his journey from working on the frontlines to moving to contract work and later starting his own company, Acela, Inc. Major Endorsements: L3Harris's BeOn PPT App. Learn more about this amazing product here: www.l3harris.comPropper Apparel: From the outdoors to the EOC, wear Propper. www.propper.comPaladin by Acela: Move into recovery with mobile MCI refrigerated morgues: www.paladinprepare.comImpulse: Bleeding Control Kits by professionals for professionals: www.dobermanemg.com/impulseDoberman Emergency Management Group provides subject matter experts in planning and training: www.dobermanemg.comThe Readiness Lab Podcast Network: Disaster Tough Podcast is part of The Readiness Lab Podcast Network For sponsorship requests: contact@thereadinesslab.com or visit our website: www.thereadinesslab.com

Plus: A delay in the new Acela fleet is costing Amtrak $140 million and counting. And, a former NYSE President joins two other suitors for rhe bankrupt crypto exchange FTX Exchange. Charlotte Gartenberg reports. Learn more about your ad choices. Visit megaphone.fm/adchoices

Welcome aboard the Acela, listeners. Today on the FiveThirtyEight Politics podcast, we are taking a break from the campaign trail and heading to Washington, D.C., where there's quite a lot going on. House Speaker Kevin McCarthy announced last week that Republicans are opening an impeachment inquiry into President Biden. There are also just 12 days until a possible government shutdown. And some Republicans are threatening McCarthy's speakership. Politics reporter Leah Askarinam and POLITICO Playbook co-author and ABC News contributor Rachael Bade join Galen Druke to discuss. They also play a round of "Quiz of the Union," where they try to put this year's higher-than-usual number of strikes in the context of public opinion. Learn more about your ad choices. Visit megaphone.fm/adchoices